Literature DB >> 22204899

Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome.

Laura Andreoli1, Micaela Fredi, Cecilia Nalli, Rossella Reggia, Andrea Lojacono, Mario Motta, Angela Tincani.   

Abstract

Multidisciplinary approach and patient counselling have been the key points in the improvement of the management of pregnancy in women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Most of these women can have successful pregnancy when thoroughly informed and instructed on several different issues. Disease activity should be in stable remission prior to pregnancy in order to reduce the chance for flare during pregnancy. To this purpose, medications must be modulated: "safe" drugs should be continued throughout pregnancy, embryotoxic/foetotoxic drugs should be withdrawn timely, and beneficial drugs such as low dose aspirin and heparin should be added for prophylaxis of maternal and foetal outcome, especially in the presence of antiphospholipid antibodies. The safety profile of anti-rheumatic drugs during pregnancy and breastfeeding should be kept constantly updated, as new data from inadvertent exposure accumulates and new drugs (especially biological agents) are available. Patients may carry autoantibodies that can negatively affect the baby, being neonatal lupus the prototypical case of passively acquired autoimmunity. Research has been greatly active in this field and more information on risk stratification and management are now available for counselling. The effect of both autoantibodies and drug exposure has been evaluated in the offspring: some concerns about learning disabilities have been raised, but these are treatable conditions that are likely to be overcome. To counsel a woman with SLE/APS during childbearing age means also to deal with contraception. Despite the "preferred choice" - combined oral contraceptive - may not be suitable for most of the patients, other options are available and should be offered and discussed with the patient. Fertility is not generally affected in SLE/APS patients, but those cases who require assisted reproduction techniques should be carefully evaluated and managed. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22204899     DOI: 10.1016/j.jaut.2011.11.010

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  17 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

2.  Pregnancy and primary biliary cirrhosis: a case-control study.

Authors:  Annarosa Floreani; Chiara Infantolino; Irene Franceschet; Ivette Magne Tene; Nora Cazzagon; Alessandra Buja; Vincenzo Baldo; M Eric Gershwin; Maria Teresa Gervasi
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 3.  The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias.

Authors:  Carlo Selmi; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 4.  Clinical features of new-onset systemic lupus erythematosus during pregnancy in Central China: a retrospective study of 68 pregnancies.

Authors:  Xiaodan He; Dongbin Jiang; Zhenbo Wang; Yao Li; Jingjing Wang; Dalin Xu; Jianqiang Chen; Xiaokang Liu; Guanmin Gao
Journal:  Clin Rheumatol       Date:  2020-10-16       Impact factor: 2.980

Review 5.  Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?

Authors:  Guilherme R de Jesús; Gustavo Rodrigues; Nilson R de Jesús; Roger A Levy
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

6.  A case of ANCA-associated vasculitis presenting de novo in pregnancy, successfully treated with rituximab.

Authors:  A Pefanis; D S Williams; H Skrzypek; A Fung; K Paizis
Journal:  Obstet Med       Date:  2018-07-26

Review 7.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 8.  Autoimmunity in 2012.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

9.  Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome.

Authors:  Merlijn Wind; Maike Hendriks; Marieke Sueters; Y K Onno Teng; Bernadette T J van Brussel; Jeroen Eikenboom; Cornelia F Allaart; Hildo J Lamb; Hans-Marc J Siebelink; Maarten K Ninaber; Nan van Geloven; Jan M M van Lith; Tom W J Huizinga; Ton J Rabelink
Journal:  Lupus Sci Med       Date:  2021-05

10.  Pregnancy Outcomes in Systemic Lupus Erythematosus Women: A single tertiary centre experience.

Authors:  Nihal Al-Riyami; Bushra Salman; Amani Al-Rashdi; Tamima Al-Dughaishi; Rahma Al-Haddabi; Batool Hassan
Journal:  Sultan Qaboos Univ Med J       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.